Biogen Analysts Lower Their Forecasts After Q4 Results

Biogen Inc BIIB reported better-than-expected earnings for its fourth quarter on Wednesday.The company posted fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of$ 3.35. The company reported sales of $2.46 billion, up 2% year over on constant currency and 3% on a reported basis, beating the consensus of$ 2.40 billion.Multiple sclerosis revenue of $1.07 billion decreased by 8% (down 9% on constant currency). The multiple sclerosis drug Tysabri sales were down to$ 415.4 million from $464.7 m ...